

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

Phospho-cdc25C (Ser216) Antibody

RRID:AB_2075150

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9528, RRID:AB_2075150

Antibody Information

URL: http://antibodyregistry.org/AB_2075150

Proper Citation: Cell Signaling Technology Cat# 9528, RRID:AB_2075150

Target Antigen: Phospho-cdc25C (Ser216)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W

Antibody Name: Phospho-cdc25C (Ser216) Antibody

Description: This polyclonal targets Phospho-cdc25C (Ser216)

Target Organism: h, human

Antibody ID: AB_2075150

Vendor: Cell Signaling Technology

Catalog Number: 9528

Record Creation Time: 20250819T235406+0000

Record Last Update: 20250820T064603+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-cdc25C (Ser216) Antibody.

No alerts have been found for Phospho-cdc25C (Ser216) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Joo YK, et al. (2025) The mitotic ATR-Chk1 pathway promotes CDK1 activity for faithful chromosome segregation. Cell reports, 44(8), 116019.

Hernandez Borrero L, et al. (2021) A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53. eLife, 10.

El-Chaar NN, et al. (2021) Topsentinol L Trisulfate, a Marine Natural Product That Targets Basal-like and Claudin-Low Breast Cancers. Marine drugs, 19(1).

Stewart E, et al. (2018) Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses. Cancer cell, 34(3), 411.